Back to Journals » Psoriasis: Targets and Therapy » Volume 9

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India

Authors Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK

Received 13 October 2017

Accepted for publication 11 January 2019

Published 3 May 2019 Volume 2019:9 Pages 19—27

DOI https://doi.org/10.2147/PTT.S154073

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Uwe Wollina


Leelavathy Budamakuntla,1 HV Shree-Lakshmi,1 Akshi Bansal,1 Shankar Kumar Venkatarayaraju2

1Department of Dermatology, Venerology and Leprosy, Bangalore Medical College and Research Institute, Bengaluru, Karnataka 560002, India; 2Department of Endocrinology, MS Diabetes Centre, Indiranagar, Bangalore 560038, India

Abstract: Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords “anti-CD6”, “psoriasis”, “phase trials”, “case series”, and “case reports”. The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.

Keywords: psoriasis, biologic, monoclonal antibody, anti-CD6, Humanised IgG1 monoclonal antibody, anti CD6

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]